期刊文献+

肾透明细胞癌组织中CMTM家族的表达及意义 被引量:3

Expression of CMTM3 and CMTM5 in clear cell renal cell carcinoma and its significance
原文传递
导出
摘要 目的探讨CMTM家族(CKLF—like MARVEL transmembrane domain—containing family)成员CMTM3和CMTM5在肾透明细胞癌(clear cell renal cell carcinoma,ccRCC)组织中的表达及意义。方法ccRCC标本75例,男50例,女25例。年龄(59±10)岁。2009AJCC分期I期34例,Ⅱ期23例,Ⅲ期14例,Ⅳ期4例。Fuhrman核分级I级3例,I~Ⅱ级1例,Ⅱ级35例,Ⅱ~Ⅲ级10例,Ⅲ级18例,Ⅲ~Ⅳ级3例,Ⅳ级5例。应用免疫组织化学方法结合组织微阵列技术检测ccRCC组织及相应正常肾组织中CMTM3、CMTM5蛋白的表达情况,综合临床资料进行分析。结果正常肾组织中CMTM3、CMTM5蛋白阳性表达率分别为98.7%和97.3%,ccRCC组织的阳性表达率分别为44.0%和68.O%,组间差异有统计学意义(P〈0.05)。ccRCC组织中CMTM3、CMTM5蛋白表达程度与性别、年龄、分期、病理分级无明显相关(P〉0.05)。结论CMTM3和CMTM5是ccRCC抑癌基因,其突变或异常甲基化可能在肾癌的发生过程中起重要作用,有望成为肾癌的早期诊断指标。 Objective To investigate the expression of CKLF-like MARVEL transmembrane (CMTM) domain-containing family in clear cell renal cell carcinoma (ccRCC) and its significance. Methods Seventy-five samples of ceRCC were collected, including 50 males and 25 females, mean age (59 + 10) years. There were 34 cases in clinical stage I, 23 cases in stage II, 14 cases in stage III and 4 cases in stage IV. The pathological differentiation was 3 cases of grade I, 1 case of grade I - II, 35 cases of grade II, 10 cases of grade II -III, 18 cases of grade lII, 3 cases of grade III- IV and 5 cases of grade IV. The expression of CMTM3 and CMTM5 proteins in 75 cases of ccRCC and corresponding adjacent normal kidney tissues was detected by tissue microarray and immunohistochemistry. Results The positive expres- sion rate of CMTM3 and CMTM5 was 98.7% , 97.3% in the adjacent normal kidney tissues, and 44.0% , 68.0% in ccRCC tissues (P 〈 0.05). The expression of CMTM3 and CMTM5 had no correlation with the gender, age, clinical staging and pathological differentiation (P 〉 0. 05). Conclusion CMTM3 and CMTM5 could be ccRCC suppressor genes, and their mutation or methylation might be an early event in the carcinogenesis of ccRCC, thus promise them to be potential biomarkers in early diagnosis.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2013年第2期123-125,共3页 Chinese Journal of Urology
关键词 CMTM家族 肾透明细胞癌 免疫组织化学 组织微阵列 CKLF-like MARVEL transmembrane domain-containing family Clear cell renal cellcarcinoma Immunohistochemistry Tissue microarray
  • 相关文献

参考文献15

  • 1Gupta K,Miller JD,Li JZ. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma(mRCC):a literature review[J].Cancer Treatment Reviews,2008,(3):193-205.doi:10.1016/j.ctrv.2007.12.001.
  • 2马建辉,李鸣,张思维,那彦群,陈万青.中国部分市县肾癌及泌尿系其他恶性肿瘤发病趋势比较研究[J].中华泌尿外科杂志,2009,30(8):511-514. 被引量:52
  • 3Wang Y,Li J,Cui Y. CMTM3,located at the critical tumor suppressor locus 16p22.1,is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis[J].Cancer Research,2009.5194-5201.
  • 4Shao L,Cui Y,Tao Q. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines[J].Clinical Cancer Research,2007.5756-5762.
  • 5Guo X,Li T,Wang Y. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha[J].Biochemical and Biophysical Research Communications,2009.139-142.
  • 6Niu J,Li H,Zhang Y. Aberrant expression of C KLF-like MARVEL transmembrane member 5(CMTM5)by promoter methylation in myeloid leukemia[J].Leukemia Research,2011.771-776.
  • 7Li P,Liu K,Li L. Reduced C MTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer[J].International Journal of Gynecological Cancer,2011.1248-1255.
  • 8萧云备,李晶,张晓威,刘振华,郁卫东,乔正国,牛屹东,徐涛,王晓峰.趋化素样因子超家族成员5对前列腺癌侵袭行为的影响[J].中华泌尿外科杂志,2012,33(12):943-946. 被引量:1
  • 9宣寒青,黄翼然,刘东明,薛蔚,陈奇.von Hippel-Lindau抑癌基因在散发性肾透明细胞癌中的突变及其意义[J].中国癌症杂志,2007,17(6):453-456. 被引量:3
  • 10Caldeira JR,Prando EC,Quevedo FC. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer[J].BMC Cancer,2006.48-57.

二级参考文献38

  • 1张宁,龚侃,果宏峰,那熙,吴关,杨新宇,辛殿旗,那彦群.散发性肾透明细胞癌组织中VHL基因突变、血管内皮生长因子表达及其与微血管形成的关系[J].中华医学杂志,2004,84(19):1620-1624. 被引量:15
  • 2孙晓杰,黄常志.PI3K-Akt信号通路与肿瘤[J].世界华人消化杂志,2006,14(3):306-311. 被引量:81
  • 3张思维,陈万青,孔灵芝,李连弟,鲁凤珠,李光琳,孟佳,赵平.中国部分市县1998~2002年恶性肿瘤的发病与死亡[J].中国肿瘤,2006,15(7):430-448. 被引量:171
  • 4李连弟,饶克勤.中国试点市县恶性肿瘤的发病与死亡第1卷(1988-1992).北京:中国医药科技出版社,2002:263-289.
  • 5李连弟,饶克勤.中国试点市县恶性肿瘤的发病与死亡第2卷(1993-1997).北京:中国医药科技出版社,2003:269-295.
  • 6李连弟,饶克勤,孔灵芝,等.中国试点市县恶性肿瘤的发病与死亡第3卷(1999-2002).北京:人民卫生出版社,2007:314-316.
  • 7Jensen OM, Parkin DM, MacLennan R, et al. Cancer registration: principles and methods. IARC Scientific Publication No. 95. Lyon:IARC, 1991:101 -107.
  • 8Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19. Lyon: IARC, 1994: 35 -49.
  • 9Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC Technical Report No. 42. Lyon: IARC, 2005:11 38.
  • 10Felay J. The IARCcrgTools program, http://www, iacr. com. fr/ iarccrgtools, htm. IACR. Lyon. 2006.

共引文献53

同被引文献17

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部